Oral Zn-Telomir for Advanced Triple-Negative Breast Cancer
Part of Cancer, Skin clinical trials.
This trial tests a new oral medication called Zn-Telomir in patients with triple-negative breast cancer that has spread or cannot be surgically removed. The drug may help slow or shrink tumors in people whose cancer has grown despite prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with triple-negative breast cancer (a type without HER2 or hormone receptors) confirmed by biopsy or cell sample
- Cancer is locally advanced and cannot be removed surgically, or has spread to other parts of the body
- Previous cancer treatments stopped at least 28 days ago, and cancer has progressed after prior therapy
- At least one measurable tumor visible on imaging scans
- Age 18 or older with expected survival of at least 12 weeks
- Willing to use effective birth control during treatment and for 3 months after, and able to provide informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Hear when a new Advanced Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.